Immunotherapy after chemotherapy slows progression of cancer in metastatic bladder cancer patients
T
reating metastatic bladder cancer patients with immunotherapy immediately after their chemotherapy significantly slows down the progression of cancer, suggests a study based on a clinical trial.
The clinical trial led by Mount Sinai researchers has been published in the Journal of Clinical Oncology.
The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomised Phase 2 trial tested this treatment in 108 patients.
The trial tested immunotherapy known as pembrolizumab after patients were treated with platinum-based chemotherapy in one group of patients and used a placebo after the same type of chemotherapy in a second group. The time until cancer progressed was approximately 60 per cent longer for the pembrolizumab group compared with the control group.
"This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial cancer, a disease characterized by a paucity of advances in decades," said lead author Matthew Galsky, MD, Co-Director of the Center of Excellence for Bladder Cancer at Mount Sinai.
✔️ Immunotherapy after chemotherapy slows progression of cancer in metastatic bladder cancer patients
💕 Found this article helpful? Spread the word and support us!